ArticleJournal of gastrointestinal oncology2021

Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Verena Schlintl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.